NCT05263895

Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation

A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF PF-07321332 FOLLOWING ORAL ADMINISTRATION OF 4 DIFFERENT FORMULATIONS RELATIVE TO THE COMMERCIAL TABLET FORMULATION IN HEALTHY ADULT PARTICIPANTS UNDER FASTED CONDITIONS

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to estimate the relative bioavailability of PF-07321332 in different formulations in healthy adult participants.

Conditions

• Bioavailability

Interventions

Type	Name	Description
DRUG	PF-07321332/ritonavir	PF-07321332 ritonavir will be administered as single dose orally
DRUG	PF-07321332/ritonavir	PF-07321332 ritonavir will be administered as single oral dose orally.
DRUG	PF-07321332/ritonavir	PF-07321332 ritonavir will be administered as single oral dose orally.
DRUG	PF-07321332/ritonavir	PF-07321332 ritonavir will be administered as single oral dose orally.
DRUG	PF-07321332	PF-07321332 will be administered as single oral dose orally.

Timeline

• Start date: 2022-03-03
• Primary completion: 2022-05-16
• Completion: 2022-05-16
• First posted: 2022-03-03
• Last updated: 2025-06-11
• Results posted: 2025-06-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study